Drug Science and University College London (UCL) are teaming up to crack the code on MDMA-assisted psychotherapy, focusing on the often overlooked but oh-so-crucial psychotherapeutic aspect. This dynamic duo aims to polish the therapeutic model, appease the FDA’s worries about combo therapy, therapist training, and long-term perks. Despite previous trials hinting at MDMA magic, the FDA recently said, “Not so fast!” requiring more proof. Enter this collaboration, ready to innovate for better safety and effectiveness, with participant recruitment set to start in 2025.
Drug Science, a UK-based independent charity untainted by political or commercial agendas, is diving into the psychological workings of MDMA. They’re even testing it on psychotherapists who know their way around a mental maze. The mission? To elevate MDMA-assisted therapy to mainstream respectability.
UCL, the multidisciplinary heavyweight founded in 1826, brings its brainpower to the table, boasting a vibrant community of over 16,000 staff and 50,000 students. For the scoop, hit up James Bunn.
Reference: https://www.drugscience.org.uk/uclmdma
Published Date: 2024-09-02